Skip to Content

Additional Content In This Section

SOLID

SOLID

Objective

Status

Results to be published

Condition
Acute Coronary Syndrome (ACS)

Description
A Clinical Outcomes Study of Darapladib versus Placebo in Persons Following Acute Coronary Syndrome to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)

Purpose

 Reduce the incidence of major cardiovascular events in high risk patients following ACS.

Phase
III

Key Inclusion Criteria

  • Hospitalized for ACS (unstable angina, non-ST segment elevation myocardial infarction (MI) or ST segment elevation MI)
  • Ability to randomize the subject within 30 days after the qualifying ACS event.
  • At least 1 additional predictors of cardiovascular risk

Key Exclusion Criteria

No major coronary artery with a blockage of more than 50%

ClinicalTrials.gov Identifier

NCT01000727

IRB Protocol Number
480848 033
Principal Investigator(s)
Rabeea Aboufakher, MD

Clinical Trial Categories

  • Cardiology
Sponsor(s)
GlaxoSmithKline
Contact
Dianne Vold, LPN CCRC at 701-780-1559
or dvold@altru.org